{"entity":{"id":"da-galantamine","kind":"drug","name":"Galantamine","aka":[],"tldr":"Galantamine is a tablet for mild-to-moderate dementia of the Alzheimer’s type. It is not approved for vascular, frontotemporal, or Lewy body dementia.","summary":"US labeling is specific to the Alzheimer’s type. Using it off-label for another subtype needs a clinician who has weighed limited benefit against harm.","status":"approved","asOf":"2026-09-21","links":[{"label":"FDA label index","url":"https://www.accessdata.fda.gov/scripts/cder/daf/"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":["da-target-ache"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Razadyne","modality":"small molecule","mechanism":"Cholinesterase inhibitor.","approvals":[{"region":"US","year":2001,"indication":"Mild-to-moderate dementia of the Alzheimer’s type"},{"region":"EU","year":2000,"indication":"Alzheimer’s dementia"},{"region":"UK","year":2000,"indication":"Alzheimer’s dementia"},{"region":"JP","year":2011,"indication":"Alzheimer’s dementia"},{"region":"CN","year":2006,"indication":"Alzheimer’s dementia"},{"region":"AU","year":2001,"indication":"Alzheimer’s dementia"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/da-galantamine/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"target":[{"id":"da-target-ache","kind":"target","name":"Acetylcholinesterase","route":"/targets/da-target-ache/"}],"technology":[{"id":"da-tech-cholinesterase-inhibitors","kind":"technology","name":"Cholinesterase inhibitors","route":"/technologies/da-tech-cholinesterase-inhibitors/"}]}}